Metformin Eg (Metformin Hydrochloride)

Metformin activates AMP‑activated protein kinase (AMPK) in the liver, which suppresses gluconeogenesis and reduces glucose output. It also enhances insulin‑mediated glucose uptake in skeletal muscle and adipose tissue, and modestly decreases intestinal glucose absorption, collectively improving overall glycemic control.

The specific dose of Metformin EG is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Metformin may be used during pregnancy when the benefits outweigh potential risks, such as in gestational diabetes, but this decision must be made by a qualified healthcare professional. Limited data are available for breastfeeding; the prescriber should evaluate the risk‑benefit profile for each patient.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metformin is often preferred as first‑line therapy for type 2 diabetes because it improves insulin sensitivity without causing weight gain and has a low risk of hypoglycemia when used alone. Other classes, such as sulfonylureas or insulin, may cause weight gain and higher hypoglycemia risk, making metformin a cost‑effective and widely accepted option.

Metformin EG should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Metformin EG is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, dehydration, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin EG is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and those receiving iodinated contrast agents for imaging studies without appropriate renal function monitoring.